Biohaven finds it hard to please in Covid times
A negative reaction to positive migraine data sends Biohaven down.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Holding a contingent value right in uncertain times
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
Vantage's coronavirus roundup
All of Vantage's Covid-19 stories in one place: share price reactions, clinical trial delays, cost estimates, and more. This page will be updated as our coverage…
Astrazeneca throws Silence an $80m lifeline
Silence has received an important validation, but making progress could be tough.
Bispecifics keep the business development fires burning
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
After Takeda endorsement Curadev’s Sting attracts Bayer
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
First clinical data show biopharma the way against Covid-19
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
